|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on October 12, 2004
Clinical Discovery Technologies, Bristol Myers Squibb, Pennington, NJ 08648
Corresponding Author: estelle.fach{at}bms.com
Summary Objective: The purpose of this study was to identify in vitro and then prioritize a tractable set of protein biomarker candidates of atherosclerosis that may eventually be developed to measure the extent, progression, regression and stability of atherosclerotic lesions. Methods and results: A study was conducted using an in vitro foam cell model based on the stimulation of differentiated THP1 cells with oxidized low density lipoprotein (oxidized LDL) as compared to low density lipoprotein (LDL). Analysis of the proteins contained in the cell supernatant using proteome scanning technology identified fifty-nine proteins as being increased, fifty-seven with no statistically measurable difference, and seventeen decreasing in abundance following treatment with oxidized LDL, as compared to LDL. From the upregulated list, proteins were prioritized based on their analytical confidence as well as their relevance to atherosclerosis pathways. Conclusions: Within the group of increased abundance, seven family of proteins were of particular interest: fatty acid-binding proteins, chitinase-like enzymes, cyclophilins, cathepsins, proteoglycans , urokinasetype plasminogen activator receptor and a macrophage scavenger receptor.
Revised on October 20, 2004
Accepted on October 20, 2004
In vitro biomarker discovery for atherosclerosis by proteomics
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
A. V. G. Edwards, M. Y. White, and S. J. Cordwell The Role of Proteomics in Clinical Cardiovascular Biomarker Discovery Mol. Cell. Proteomics, October 1, 2008; 7(10): 1824 - 1837. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. P. M. Lutgens, K. B. J. M. Cleutjens, M. J. A. P. Daemen, and S. Heeneman Cathepsin cysteine proteases in cardiovascular disease FASEB J, October 1, 2007; 21(12): 3029 - 3041. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Bagnato, J. Thumar, V. Mayya, S.-I. Hwang, H. Zebroski, K. P. Claffey, C. Haudenschild, J. K. Eng, D. H. Lundgren, and D. K. Han Proteomics Analysis of Human Coronary Atherosclerotic Plaque: A Feasibility Study of Direct Tissue Proteomics by Liquid Chromatography and Tandem Mass Spectrometry Mol. Cell. Proteomics, June 1, 2007; 6(6): 1088 - 1102. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. M. Blanco-Colio, J. L. Martin-Ventura, F. Vivanco, J.-B. Michel, O. Meilhac, and J. Egido Biology of atherosclerotic plaques: What we are learning from proteomic analysis Cardiovasc Res, October 1, 2006; 72(1): 18 - 29. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. P. Conway and M. Kinter Proteomic and Transcriptomic Analyses of Macrophages with an Increased Resistance to Oxidized Low Density Lipoprotein (oxLDL)-induced Cytotoxicity Generated by Chronic Exposure to oxLDL Mol. Cell. Proteomics, October 1, 2005; 4(10): 1522 - 1540. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| All ASBMB Journals | Journal of Biological Chemistry |
| Journal of Lipid Research | ASBMB Today |